Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: Reporting extended results from phase III clinical trials

Annals of Neurology

Volumn 46, Issue 1, 1999, Pages 132-134

  Goodkin, D E ^a   Reingold, S ^b   Sibley, W ^b   Wolinsky, J ^b   McFarland, H ^b   Cookfair, D ^b   Lublin, F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMIR ACETATE; INTERFERON BETA SERINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DEMOGRAPHY; DISABILITY; DRUG EFFECT; DRUG TOLERANCE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTHESIS; MULTIPLE SCLEROSIS; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE III; HUMANS; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0033006132     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199907)46:1<132::AID-ANA22>3.0.CO;2-Z     Document Type: Review

References (7)

1. IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
2. Jacobs L, Cookfair D, Rudick R, et al. Intramuscular interferon-β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294
3. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276
4. IFNB Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285
5. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramir acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998;50:701-708
6. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276:637-639
7. Haynes RB, Mulrow CD, Huth EJ, et al. More informative abstracts revisited. Ann Intern Med 1990;113:69-76